SCHEMBL2194277

SCHEMBL2194277

Brc1ccc(CN(I)I)cc1.Cn1ccn(-c2ccccc2)c1=[Pt]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
ALOX15B O15296 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
PYCR1 P32322 3/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
CXCR3 P49682 1/20 0.32
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
MAOB P27338 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195488 0.91 TSHR (0.34) BCHEL3MBTL1CYP1A2CYP3A4CYP2D6
SCHEMBL2196788 0.88 CYP2C19 (0.36) BCHEALOX15BCYP1A2CYP2C19ALDH1A1
SCHEMBL2192772 0.87 CYP19A1 (0.34) TSHRALDH1A1KMT2A
SCHEMBL2192093 0.87 CYP19A1 (0.34) L3MBTL1ALDH1A1MAPT
SCHEMBL2196965 0.85 ALOX15B (0.39) BCHEL3MBTL1ALOX15BPYCR1MAPT
SCHEMBL2197038 0.85 PYCR1 (0.37) BCHEL3MBTL1PYCR1TSHRHTT
SCHEMBL2194356 0.82 LMNA (0.32) BCHEL3MBTL1HTTMEN1KMT2A
SCHEMBL2195398 0.79 TSHR (0.41) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2192094 0.79 CYP11B1 (0.36) BCHEL3MBTL1CYP1A2CYP3A4CYP2D6
SCHEMBL2192106 0.78 CXCR3 (0.46) BCHEL3MBTL1PYCR1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 BCHE 2321/4885L3MBTL1 2187/4885ALOX15B 1480/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 BCHE 2321/4885L3MBTL1 2187/4885ALOX15B 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.